Harvoni Study: 97% of Hepatitis C Patients Cured

Of Interest

Mar 20, 2017

2017 / Hepatitis C: Down but Not Out - Oral Direct-Acting Agent Therapy for HCV

Multiple oral DAA regimens show high rates of safety, tolerability, and efficacy for treatment of HCV genotype 1 infection, particularly among persons without cirrhosis.

Six DAA regimens showed high sustained virologic response (SVR) rates (>95%) in patients with HCV genotype 1 infection without cirrhosis, including those with HIV co-infection. Effective treatments for HCV genotype 3 infection are limited (2 DAA regimens). Patients with hepatic decompensation, particularly those with Child–Turcotte–Pugh class C disease, had lower SVR rates (78% to 87%) than other populations. The addition of ribavirin was associated with increased SVR rates for certain DAA regimens and patient groups. Overall rates of serious adverse events and treatment discontinuation were low (<10% in the general population); regimens that included ribavirin had more mild or moderate adverse events than those without.

Prime Therapeutics Study Finds 97 Percent of Hepatitis C Patients Cured with Harvoni® Treatment
Mar 21, 2017

Real-world data show nearly all patients completing therapy were cured.

ST. PAUL, Minn. – Nearly all patients who completed at least eight weeks of hepatitis C treatment with Gilead’s Harvoni® (ledipasvir/sofosbuvir) were cured of the disease, according to Prime Therapeutics LLC (Prime). Prime, a pharmacy benefit manager (PBM) serving nearly 20 million members nationally will present the data next week at the Academy of Managed Care Pharmacy’s 2017 Annual Meeting. The results are similar to clinical trial data on the treatment, which found cure rates of 94 to 99 percent.

For the study, Prime researchers reviewed data from 311 individuals who received at least eight weeks of Harvoni therapy and had a sustained virologic response (SVR) test result provided to the pharmacy between 12 to 24 weeks following Harvoni use. The SVR is used determine treatment response. Researchers found 301 of 311 members (96.8 percent) had a SVR laboratory result indicating a cure.

“Prime’s real-world data reflect findings from clinical trials. Our members who received at least eight weeks of Harvoni through Prime Therapeutics Specialty PharmacyTM had a very high likelihood of being cured of this disease,” said Cathy Starner, PharmD, principal health outcomes researcher at Prime.
Download (PDF)